Kura Oncology : Corporate Presentation - November 2023

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER

Corporate Presentation - November 2023

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, and our expectations regarding the therapeutic and commercial potential of our product candidates. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue," "anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the COVID-19 pandemic may continue to have an impact on our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials; our product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; and we may not be able to obtain additional financing. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and uncertainties.

All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This presentation also contains statistical and clinical data obtained from and prepared by third parties. The recipient is cautioned not to give undue weight to such disclosures. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation.

2

Investment Highlights

Targeted	Advancing a pipeline of novel therapies, forging new scientific and clinical paths to give patients a better
Oncology	chance for long-term durable remissions
	Menin Inhibitor Program (Ziftomenib)
	• Potential to address up to 50% of acute leukemias through monotherapy and combinations
	• Durable responses and encouraging safety and tolerability observed in relapsed/refractory AML
	• 35% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose
Proprietary	• Completion of enrollment in Phase 2 registration-directed trial in NPM1-mutant AML expected by mid-2024
• Preliminary data from combo study in NPM1-m and KMT2A-r AML anticipated in early Q1 2024
Pipeline
Farnesyl Transferase Inhibitor Programs (Tipifarnib & KO-2806)
	• Durable responses as a monotherapy in recurrent/metastatic HRAS-mutant HNSCC patients
	• Compelling safety profile and activity observed with tipifarnib plus alpelisib in PIK3CA-dependent HNSCC
	• Preclinical data support clinical combinations of next-gen FTI KO-2806 with adagrasib and cabozantinib
	• Clinical collaboration with Mirati to evaluate KO-2806 and adagrasib in KRASG12C-mutated NSCLC
	• First patient dosed in FIT-001 Phase 1 dose-escalation trial of next-generation FTI KO-2806
Strong	• $25 million strategic equity investment from Bristol Myers Squibb
Financials	• $452.6 million in cash as of September 30, 2023* provides runway into mid-2026

* Cash, cash equivalents and short-term investments	3

Experienced Leadership Team and Board of Directors

Leadership Team

Troy Wilson, Ph.D., J.D.	Teresa Bair, J.D.	Stephen Dale, M.D.	Kathy Ford
President &	Chief Legal Officer	Chief Medical Officer	Chief Operating Officer
Chief Executive Officer

	Pete De Spain		Mollie Leoni, M.D.	Francis Burrows, Ph.D.		Tom Doyle
	Executive Vice President,	Executive Vice President,	Senior Vice President,	Senior Vice President,
Investor Relations & Corporate		Clinical Development	Translational Research	Finance & Accounting
	Communications
	Board of Directors
	Troy Wilson, Ph.D., J.D.		Faheem Hasnain		Helen Collins, M.D.		Thomas Malley
	Chairman		Lead Independent Director
	Carol Schafer		Diane Parks		Mary Szela

Brian Powl

Chief Commercial Officer

Roger Bakale, Ph.D.

Senior Vice President,

Manufacturing and

Supply Chain

4

Drug Candidate Pipeline

PROGRAM	CLINICAL TRIAL	PLANNED

STUDY STARTUP

PHASE 1

REGISTRATION DIRECTED

		NPM1-mutant acute myeloid leukemia (AML)
	KOMET-001	Non-NPM1-m/Non-KMT2A-r AML
	Monotherapy
	(Relapsed/ refractory)
		KMT2A-rearranged ALL
ZIFTOMENIB	KOMET-007	NPM1-mutant AML
Menin Inhibitor	Combinations with
ven/aza, 7+3
	(Relapsed/ refractory,	KMT2A-rearranged AML
	frontline)
	KOMET-008	NPM1-mutant AML
	Combinations with
	gilteritinib, FLAG-IDA,
	LDAC	KMT2A-rearranged AML
	(Relapsed/ refractory)
TIPIFARNIB	KURRENT-HN
Farnesyl Transferase	Combination with	PIK3CA-dependent HNSCC
Inhibitor (FTI)	alpelisib
KO-2806	FIT-001	KRAS G12C-MutantNon-Small Cell Lung Cancer
Combinations with
Next-Generation FTI	adagrasib and	Clear Cell Renal Cell Carcinoma
	cabozantinib

5

ZIFTOMENIB: MENIN-KMT2A/MLL INHIBITOR IN ACUTE LEUKEMIAS

Ziftomenib Has Potential to Become a Transformational Therapy for AML

• Targets foundational mutations at the core of up to 50% of AML cases
• Has demonstrated durable CRs and maintained count recovery as a monotherapy in late-line AML patients
• Favorable tolerability and once-daily oral dosing, ideal for chronic therapy
• Strong mechanistic synergy with current standards of care
• Optimal pharmaceutical properties for combinations

• We believe ziftomenib has ideal properties to become a backbone of therapy across the continuum of care for AML patients
• Pursuing a broad-based ziftomenib development program coupled with potential to convert 50% of AML from an acute to chronic condition

7

Ziftomenib Targets the Menin-KMT2A Pathway, a Foundational Target in AML

• NPM1-m and KMT2A-r drive overexpression of HOXA9/MEIS1 genes, critical for transformation to AML
• KMT2A(MLL) sits upstream from major AML targets (i.e., FLT3, IDH1/2, DNMT3A)
• KMT2A(MLL)-dependentgenes contribute to therapeutic resistance and relapse to current therapies
• Menin inhibition downregulates HOXA9/MEIS1, leading to differentiation of leukemic blasts

Proliferation

genes

'Stemness'

genes

Myeloid lineage differentiation genes

1. Lu et al. Cancer Cell 2016;30(1):92-107; 2. Ferreira et al. Oncogene 2016;35(23):3079-82; 3. Jeong et al. Nat. Genet 2014;46(1):17-23; 4. Wang et al. Blood 2005;106(1):254-64; 5. Chowdhury et al. EMBO Rep 2011;12(5):463-9; 6. Schmidt et al. Leukemia 2019;33(7):1608-19; 7. Xu et al. Cancer Cell

2016;30(6):863-78; 8. Collins & Hess. Curr Opin Hematol 2016;23(4):354-61; 9. Brunetti et al. Cancer Cell 2018; 34(3):499-512.	8

KOMET-001 Phase 1/2 Study of Ziftomenib in Relapsed/Refractory AML

Phase 1a

Dose Escalation

Completed

50 mg	100 mg	~	1000 mg
QD	QD		QD

NPM1-m,KMT2A-r, Other

Phase 1b	Phase 1b	Phase 2
Validation Cohorts	Expansion	Registration-Enabling
Completed	Completed	(Ongoing)
	Ongoing
Cohort 1: 200 mg QD	Expansion of 600 mg QD
	600 mg
Cohort 2: 600 mg QD		QD
NPM1-mor KMT2A-r	NPM1-m	NPM1-m

OBJECTIVES

• Safety and tolerability
• Pharmacokinetics
• Early evidence of antitumor activity

• Safety and tolerability
• Pharmacokinetics
• Clinical activity

Continue enrollment of Phase	• Primary endpoint:
1b validation cohort(s)	•	CR/CRh
consistent with FDA's Project
Optimus	• Secondary endpoints:
	•	Duration of CR/CRh
• Safety and tolerability	•	Transfusion independence
• Pharmacokinetics	•	CR/CRh MRD negativity
• Clinical activity	•	Adverse events

CR, complete remission; CRh, complete remission with partial hematological recovery; FDA, United States Food and Drug Administration;

MRD, measurable residual disease; R/R, relapsed/refractory; RP2D, recommended phase 2 dose.

9

Ziftomenib Demonstrates Encouraging Safety Profile in NPM1-mutant Patients Treated at 600 Mg Dose

≥ 20% Treatment-Emergent Adverse Events, n (%)	NPM1-m, n = 20
Patients with TEAEs (All Grades)	19 (95)
Diarrhea	9 (45)
Hypokalemia	8 (40)
Nausea	6 (30)
Anemia	6 (30)
Back pain	6 (30)
Epistaxis	5 (25)
Patients with TEAEs (≥Grade 3)	17 (85)
Anemia	5 (25)
Thrombocytopenia	4 (20)

≥ 20% Treatment-Related Adverse Events, n (%)	NPM1-m, n = 20
Patients with TRAEs (All Grades)	12 (60)
Nausea	4 (20)
Differentiation Syndrome	4 (20)
Patients with TRAEs (≥Grade 3)	6 (30)
N/A

• No reports of drug-induced QTc prolongation
• 1 report of grade 3 differentiation syndrome
  • Manageable with mitigation strategy
• Other reports of DS Grade ≤ 2

Fathi et al. EHA 2023 #LB2713 (preliminary data as of April 12, 2023)	10